Adalimumab-Ryvk
Simlandi
NADAC/unit
$488.7215
No Shortage
Tier 1: 32.8%
PA Req: 173.3%
vs. brand Simlandi: Generic saves up to -4787% per unit
Active Shortages
2025-11-13 Discontinuation of the manufacture of the drug, Teva Pharmaceuticals USA, Inc.
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.